These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10500778)

  • 21. The rate of disease progression predicts the quality of remissions following intensive chemotherapy for myelodysplastic syndromes.
    Hirst WJ; Mufti GJ
    Leuk Res; 1994 Nov; 18(11):797-804. PubMed ID: 7967705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications.
    Michieli M; Damiani D; Ermacora A; Masolini P; Raspadori D; Visani G; Scheper RJ; Baccarani M
    Br J Haematol; 1999 Feb; 104(2):328-35. PubMed ID: 10050716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
    Ferrero D; Crisà E; Marmont F; Audisio E; Frairia C; Giai V; Gatti T; Festuccia M; Bruno B; Riera L; Passera R; Boccadoro M
    Ann Hematol; 2014 Aug; 93(8):1391-400. PubMed ID: 24705888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia.
    Hu XF; Slater A; Kantharidis P; Rischin D; Juneja S; Rossi R; Lee G; Parkin JD; Zalcberg JR
    Blood; 1999 Jun; 93(12):4086-95. PubMed ID: 10361105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
    Tallman MS; Lee S; Sikic BI; Paietta E; Wiernik PH; Bennett JM; Rowe JM
    Cancer; 1999 Jan; 85(2):358-67. PubMed ID: 10023703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
    Natarajan-Amé S; Park S; Ades L; Vey N; Guerci-Bresler A; Cahn JY; Etienne G; Bordessoule D; Ravoet C; Legros L; Cheze S; Stamatoullas A; Berger E; Schmidt A; Charbonnier A; Chaury MP; Braun T; Fenaux P; Dreyfus F;
    Br J Haematol; 2012 Jul; 158(2):232-237. PubMed ID: 22571447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
    Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
    Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the
    Ades L; Prebet T; Stamatoullas A; Recher C; Guieze R; Raffoux E; Bouabdallah K; Hunault M; Wattel E; Stalnikiewicz L; Toma A; Dombret H; Vey N; Sebert M; Gardin C; Chaffaut C; Chevret S; Fenaux P
    Haematologica; 2017 Apr; 102(4):728-735. PubMed ID: 28034993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Multi-drug resistance and myelodysplastic syndromes: a possible role for remission inducing agents?].
    Wattel E; Lepelley P
    Pathol Biol (Paris); 1997 Oct; 45(8):637-42. PubMed ID: 9569929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia.
    Knauf WU; Berdel WE; Ho AD; Kreuser ED; Thiel E
    Leuk Lymphoma; 1994 Feb; 12(5-6):421-5. PubMed ID: 8180605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
    Kantarjian H; Beran M; Cortes J; O'Brien S; Giles F; Pierce S; Shan J; Plunkett W; Keating M; Estey E
    Cancer; 2006 Mar; 106(5):1099-109. PubMed ID: 16435387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes.
    Aul C; Schneider W
    Cancer; 1989 Nov; 64(9):1812-8. PubMed ID: 2790694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.
    Benderra Z; Faussat AM; Sayada L; Perrot JY; Chaoui D; Marie JP; Legrand O
    Clin Cancer Res; 2004 Dec; 10(23):7896-902. PubMed ID: 15585622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anthracycline drugs and MDR expression in human leukemia.
    Pogliani EM; Belotti D; Rivolta GF; Maffè PF; Corneo G
    Cytotechnology; 1996; 19(3):229-35. PubMed ID: 8862011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients.
    Malagola M; Damiani D; Martinelli G; Michelutti A; Cesana B; Vivo AD; Piccaluga PP; Ottaviani E; Candoni A; Geromin A; Tiribelli M; Fanin R; Testoni N; Lauria F; Bocchia M; Gobbi M; Pierri I; Zaccaria A; Zuffa E; Mazza P; Priccolo G; Gugliotta L; Bonini A; Visani G; Skert C; Bergonzi C; Roccaro AM; Filí C; Baccarani M; Russo D
    Br J Haematol; 2007 Jan; 136(1):87-95. PubMed ID: 17222198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
    Giles FJ; Kantarjian HM; Cortes JE; Faderl S; Verstovsek S; Thomas D; Garcia-Manero G; Wierda W; Ferrajoli A; Kornblau S; Mattiuzzi GN; Tsimberidou AM; Albitar M; O'Brien SM; Estey E
    Leuk Res; 2005 Jun; 29(6):649-52. PubMed ID: 15863204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Low-dose chemotherapy].
    Ogata K; Yamada T; Dan K
    Rinsho Ketsueki; 1996 Sep; 37(9):777-81. PubMed ID: 8914461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of a hematological and cytogenetic remission in a patient with a myelodysplastic syndrome secondary to Fanconi's anemia employing the S-HAM regimen.
    Verbeek W; Haase D; Schoch C; Hiddemann W; Wörmann B
    Ann Hematol; 1997 Jun; 74(6):275-7. PubMed ID: 9236512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensive chemotherapy for acute non-lymphoblastic leukemia after primary myelodysplastic syndrome.
    Martiat P; Ferrant A; Michaux JL; Sokal G
    Hematol Oncol; 1988; 6(4):299-305. PubMed ID: 3181878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New developments in the treatment of acute myeloid leukemia.
    Smeets M; de Witte T; van der Lely N; Raymakers R; Muus P
    Adv Exp Med Biol; 1999; 457():557-65. PubMed ID: 10500834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.